Wednesday, September 09, 2026 Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma Pre-existing and emerging molecular targeted therapies have been identified for the treatment of pancreatic ductal adenocarcinoma (PDAC) and exemplify the need for incorporating tumor sequencing into routine clinical practice. Tumor profiling through circulating tumor DNA (ctDNA) represents an important opportunity in PDAC because of the aggressive nature of the disease. Circulating tumor fraction (CTF) levels are highly variable within and between cancer types and influence the accuracy of plasma-based tumor profiling, and the variability and factors related to CTF levels in PDAC are not well understood. Topham JT, Beckmann HM, Karasinska JM, Loree JM, Knox JJ, Kavan P, Jonker D, Welch S, Couture F, Lemay F, Tehfe M, Harb M, Aucoin N, Ko Y-J, Tang PA, Ramjeesingh R, Meyers BM, Kim CA, Notta F, Zogopoulos G, Gallinger S, Du P, Jia S, Gill S, Tu D, O’Callaghan CJ, Schaeffer DF, Renouf DJ. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research 32: 3620-3628. 2026.https://doi.org/10.1158/1078-0432.CCR-26-0793
